Table 1 Cohort Characteristics
N (%) | Median % PSMA | Spearman-ρ; p-value | PSMA≤10% | PSMA>10% | Chi2 PSMA ≤10% vs >10% | |
|---|---|---|---|---|---|---|
Patients | 110 | 31% | 23 (21%) | 87 (79%) | ||
Gender | ||||||
Male | 36 (33%) | 30% | .11; p = .24 | 7 (19%) | 29 (81%) | p = .79 |
Female | 74 (67%) | 45% | 16 (22%) | 58 (78%) | ||
Age at diagnosis | ||||||
Median (IQR) | 57 (45–68) | .08; p = .42 | 56 (50–70) | 58 (43–68) | p = .45 | |
Range | 20–90 | 34–87 | 20–90 | |||
Site and subsite | ||||||
aMajor salivary gland | 59 (54%) | 50% | −.25; p < .01 | 7 (12%) | 52 (88%) | p = .01 |
Parotid gland | 26 | 50% | 2 | 24 | p = .06 | |
Submandibular gland | 30 | 35% | 5 | 25 | p = .50 | |
Sublingual gland | 3 | 57% | 0 | 3 | p = .37 | |
aMinor salivary and seromucous gland | 51 (46%) | 21% | 16 (31%) | 35 (69%) | ||
Oral cavity (lip/buccal mucosa/hard palate/gum) | 21 | 19% | 7 | 14 | p = .12 | |
Oropharynx (soft palate/base of tongue) | 8 | 21% | 1 | 7 | p = .54 | |
Nasal cavity/nasopharynx/maxillary sinus | 15 | 10% | 8 | 7 | p < .01 | |
Larynx/trachea | 3 | 42% | 0 | 3 | p = .37 | |
Lacrimal gland | 2 | 35% | 0 | 2 | p = .46 | |
External auditory canal | 2 | 40% | 0 | 2 | p = .46 | |
Tumour | ||||||
pT-stage (TNM 7th ed.) | ||||||
pT1 | 35 | 50% | −.18; p = .06 | 5 | 30 | p = .24 |
pT2 | 39 | 33% | 7 | 32 | p = .57 | |
pT3 | 5 | 20% | 1 | 4 | p = .96 | |
pT4a | 23 | 30% | 6 | 17 | p = .49 | |
pT4b | 8 | 13% | 4 | 4 | p = .04 | |
Nodal status | ||||||
pN0 | 99 (90%) | 33% | −.09; p = .37 | 20 (20%) | 79 (80%) | p = .58 |
pN+ | 11 (10%) | 25% | 3 (27%) | 8 (73%) | ||
Distant metastasis | ||||||
cM0 | 108 | 31% | −.01; p = .90 | 23 (21%) | 85 (79%) | p = .62 |
cM1 | 2 | 36% | 0 (0%) | 2 (100%) | ||
Resection margin | ||||||
clear (> 5 mm) | 20 (18%) | 50% | −.08; p = .43 | 2 (10%) | 18 (90%) | p = .18 |
close (1-5 mm) | 4 (4%) | 20% | 2 (50%) | 2 (50%) | p = .14 | |
positive (< 1 mm) | 86 (78%) | 30% | 19 (22%) | 67 (78%) | p = .56 | |
Perineural growth | ||||||
Present | 76 (69%) | 30% | −.02; p = .86 | 14 (18%) | 62 (82%) | p = .44 |
Absent | 32 (31%) | 45% | 8 (25%) | 24 (75%) | ||
Vasoinvasive growth | ||||||
Present | 17 (15%) | 30% | −.05; p = .64 | 5 (29%) | 12 (71%) | p = .33 |
Absent | 90 (82%) | 33% | 17 (19%) | 73 (81%) | ||
aBone invasion | ||||||
Present | 27 (25%) | 17% | −.20; p = .04 | 10 (37%) | 17 (63%) | p = .02 |
Absent | 82 (75%) | 39% | 13 (16%) | 69 (84%) | ||
Growth pattern (Perzin grade [21]) | ||||||
Tubular (grade 1) | 46 (42%) | 30% | .12; p = .21 | 10 (22%) | 36 (78%) | p = .89 |
Cribriform; < 30% solid (grade 2) | 43 (39%) | 33% | 7 (16%) | 36 (84%) | p = .32 | |
Solid (grade 3) | 20 (18%) | 46% | 6 (30%) | 14 (70%) | p = .28 | |
Treatment | ||||||
Adjuvant radiotherapy | ||||||
Yes | 102 (93%) | 33% | .14; p = .15 | 20 (20%) | 82 (80%) | p = .23 |
No | 8 (7%) | 26% | 3 (38%) | 5 (62%) | ||